Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline Steers Away from 'White Pills in Western Markets'

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Andrew Witty underlines the company's continued diversification into vaccines, consumer health and emerging markets
Advertisement

Related Content

GSK/Dr. Reddy’s Form Deal To Co-Promote Branded Generics In Emerging Markets
GSK’s Strategy in Emerging Markets: Scale, Diversification and Access
GSK’s Strategy in Emerging Markets: Scale, Diversification and Access
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
Pfizer/Wyeth: Industrializing Pharma?
Pfizer/Wyeth: Industrializing Pharma?

Topics

Advertisement
UsernamePublicRestriction

Register

PS069729

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel